Pharmacogenetics and personalised medicine: Maintain a critical approach

Prescrire International

Volumn 22, Issue 139, 2013, Pages 161-163

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; B RAF KINASE; CARBAMAZEPINE; CETUXIMAB; CLOPIDOGREL; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; GEFITINIB; IMATINIB; LAPATINIB; PANITUMUMAB; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); RNA; TAXANE DERIVATIVE; TRASTUZUMAB; VEMURAFENIB; WARFARIN;

ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL PRACTICE; COLORECTAL CANCER; DIAGNOSTIC TEST; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TREATMENT FAILURE; GENE MUTATION; GENETIC SCREENING; GOLD STANDARD; HUMAN; HYPOTHESIS; LUNG NON SMALL CELL CANCER; MELANOMA; ONCOGENE K RAS; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PHARMACOGENETICS; PHARMACOGENOMICS; PREDICTIVE VALUE; PROGNOSIS; PROGRESSION FREE SURVIVAL; RISK FACTOR; SENSITIVITY AND SPECIFICITY; STEVENS JOHNSON SYNDROME; STOMACH CANCER; THEORY-PRACTICE RELATIONSHIP;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; GENETIC TESTING; HUMANS; INDIVIDUALIZED MEDICINE; NEOPLASMS; PHARMACOGENETICS;

EID: 84880770691     PISSN: 11677422     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. US Department of Health and Human Services - "Realizing the Potential of Pharmacogenomics: Opportunities and Challenges" May 2008: 150 pages.
2. Institut national du cancer "Les tests de génétique moléculaire pour l'accès aux thérapies ciblées en France en 2011" December 2011: 53 pages.
3. Robertson JA et al. "Pharmacogenetic challenges for the health care system" Health Aff 2002; 21 (4): 155-167.
4. Afssaps "Les biomarqueurs, les produits de santé et l'Afssaps" 31 August 2011: 19 pages.
5. Prescrire Editorial Staff "Adjuvant trastuzumab for breast cancer. Longer follow-up confirms improved overall survival " Prescrire Int 2012; 21 (133): 285-287.
6. Agency for Healthcare Research and Quality "Systematic reviews on selected pharmacogenetic tests for cancer treatment: CYP2D6 for tamoxifen in breast cancer, KRAS for anti-EGFR antibodies in colorectal cancer, and BCR-ABL1 for tyrosine kinase inhibitors in chronic myeloid leukemia" 7 June 2010: 169 pages.
7. Regan MM et al. "CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine- responsive breast cancer: The breast international group 1-98 trial" J Natl Cancer Inst 2012; 104 (6): 441-451.
8. Prescrire Editorial Staff "Trastuzumab: metastatic breast cancer, in combination with docetaxel: promising, but more evaluation is needed" Prescrire Int 2006; 15 (81): 3-5.
9. Prescrire Editorial Staff "Lapatinib. For some women with metastatic breast cancer " Prescrire Int 2009; 18 (99): 9.
10. Prescrire Rédaction "trastuzumab-Herceptin° et cancers de l'estomac métastasés. Pour certains malades seulement" Rev Prescrire 2010; 30 (324): 732.
11. Prescrire Rédaction "Chimiothérapie du cancer colorectal métastasé. Fluorouracil + acide folinique, oxaliplatine, irinotécan, combinés selon les situations" Rev Prescrire 2010; 30 (320): 438-443.
12. Prescrire Rédaction "erlotinib et cancer bronchique non à petites cellules-Tarceva°. En première ligne: aussi décevant que le géfitinib" Rev Prescrire 2012; 32 (345): 498-499.
13. Prescrire Editorial Staff "Vemurafenib. Value unclear in metastatic melanoma " Prescrire Int 2012; 21 (133): 288-290.
14. Prescrire Rédaction "Leucémie myéloïde chronique, en bref" and "Leucémie myéloïde chronique: Traitement" Idées-Forces Prescrire updated November 2012: 2 pages + 8 pages.
15. U.S. FDA "Table of Pharmacogenomic Biomarkers in Drug Labels" www.fda.gov accessed 8 February 2012: 18 pages.
16. Wang L et al. "Genomics and drug response" N Engl J Med 2011; 364 (12): 1144-1153.
17. Prescrire Editorial Staff "Abacavir pretreatment screening test " Prescrire Int 2008; 17 (98): 239.
18. Prescrire Rédaction "Carbamazépine: risques accrus de troubles cutanés graves chez certains patients asiatiques" Rev Prescrire 2009; 29 (313): 820.